Mega Genomics (HKG:6667) said an independent forensic investigation found no evidence of management misconduct, according to a Tuesday Hong Kong bourse filing.

The investigation, conducted by Grant Thornton Advisory Services, reviewed the company's revenue recognition practices for genetic testing kits and the authenticity of promotional fees.

The report concluded that the company's explanations were not "evidently unreasonable," though it identified weaknesses in internal controls and procedural execution.

The board accepted the report's findings and said corrective actions and an internal control review are underway. The company emphasized that the issues had no material adverse impact on its operations or financial position.

Trading in Mega Genomics shares, suspended since April 1 pending resumption guidance compliance, will remain halted until further notice, the company said.